Nurix Therapeutics Inc. (NRIX)
14.70
-0.75 (-4.85%)
At close: Mar 03, 2025, 11:59 AM
Nurix Therapeutics Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
| Revenue | 54.55M | 76.99M | 38.63M | 29.75M | 17.82M | 31.11M | 37.45M |
| Cost of Revenue | n/a | 189.15M | 10.81M | 6.08M | 66.49M | 45.02M | 40.51M |
| Gross Profit | 54.55M | -112.16M | 27.82M | 23.67M | -48.67M | -13.91M | -3.06M |
| Operating Income | -213.03M | -155.06M | -183.87M | -117.89M | -64.98M | -22.24M | -9.74M |
| Interest Income | 19.73M | 11.12M | 3.51M | 823K | 1.21M | 776K | 818K |
| Pretax Income | -193.3M | -143.95M | -180.36M | -117.06M | -63.78M | -21.46M | -8.92M |
| Net Income | -193.57M | -143.95M | -166.04M | -117.19M | -43.24M | -21.7M | -9.43M |
| Selling & General & Admin | 45.94M | 42.9M | 38M | 31.2M | 16.31M | 8.33M | 6.67M |
| Research & Development | 221.63M | 189.15M | 184.5M | 116.43M | 66.49M | 45.02M | 40.51M |
| Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Expenses | 267.58M | 232.05M | 222.49M | 147.64M | 82.8M | 53.35M | 47.19M |
| Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 267.58M | 232.05M | 222.49M | 147.64M | 82.8M | 53.35M | 47.19M |
| Income Tax | 270K | n/a | -14.31M | 131K | -20.54M | 239K | 507K |
| Shares Outstanding (Basic) | 67.12M | 54.34M | 48.61M | 42.9M | 15.67M | 38.85M | 16.11M |
| Shares Outstanding (Diluted) | 67.12M | 54.34M | 48.61M | 42.9M | 15.67M | 38.85M | 16.11M |
| EPS (Basic) | -2.88 | -2.65 | -3.42 | -2.73 | -2.76 | -0.56 | -0.59 |
| EPS (Diluted) | -2.88 | -2.65 | -3.42 | -2.73 | -2.76 | -0.56 | -0.59 |
| EBITDA | -213.03M | -141.41M | -173.06M | -111.8M | -62.8M | -19.88M | -6.75M |
| Depreciation & Amortization | n/a | 13.65M | 10.81M | 6.08M | 2.18M | 2.35M | 2.99M |